These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12404708)

  • 41. A survey of tardive dyskinesia in psychiatric inpatients in Japan.
    Koshino Y; Madokoro S; Ito T; Horie T; Mukai M; Isaki K
    Clin Neuropharmacol; 1992 Feb; 15(1):34-43. PubMed ID: 1349507
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
    Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diabetes and development of tardive dyskinesia.
    Woerner MG; Saltz BL; Kane JM; Lieberman JA; Alvir JM
    Am J Psychiatry; 1993 Jun; 150(6):966-8. PubMed ID: 8098587
    [TBL] [Abstract][Full Text] [Related]  

  • 44. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia.
    Lee HJ; Kang SG; Choi JE; Paik JW; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
    Neuropsychobiology; 2007; 55(1):47-51. PubMed ID: 17556853
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tardive dyskinesia and ethnicity: review of the literature.
    Swartz JR; Burgoyne K; Smith M; Gadasally R; Ananth J; Ananth K
    Ann Clin Psychiatry; 1997 Mar; 9(1):53-9. PubMed ID: 9167836
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study.
    Tenback DE; van Harten PN; Slooff CJ; van Os J;
    Compr Psychiatry; 2007; 48(5):436-40. PubMed ID: 17707251
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tardive dyskinesia prevalence rates during a ten-year follow-up.
    Miller CH; Simioni I; Oberbauer H; Schwitzer J; Barnas C; Kulhanek F; Boissel KE; Meise U; Hinterhuber H; Fleischhacker WW
    J Nerv Ment Dis; 1995 Jun; 183(6):404-7. PubMed ID: 7798090
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong.
    Chiu H; Shum P; Lau J; Lam L; Lee S
    Am J Psychiatry; 1992 Aug; 149(8):1081-5. PubMed ID: 1353316
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pro- and antioxidant processes in schizophrenics with tardive dyskinesia].
    Gałecki P; Pietras T; Florkowki A
    Psychiatr Pol; 2005; 39(6):1131-41. PubMed ID: 16526180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
    Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.
    Woods SW; Morgenstern H; Saksa JR; Walsh BC; Sullivan MC; Money R; Hawkins KA; Gueorguieva RV; Glazer WM
    J Clin Psychiatry; 2010 Apr; 71(4):463-74. PubMed ID: 20156410
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tardive dyskinesia in the aged. Duration of treatment relationships.
    Toenniessen LM; Casey DE; McFarland BH
    Arch Gen Psychiatry; 1985 Mar; 42(3):278-84. PubMed ID: 2858189
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Tardive dyskinesia (review of the literature)].
    Lerner VE
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(2):124-32. PubMed ID: 2897750
    [No Abstract]   [Full Text] [Related]  

  • 54. Use of atypical antipsychotic medications in adolescent psychiatric inpatients: a comparison with inpatients who did not receive antipsychotic medications during their stay.
    Pogge DL; Young K; Insalaco B; Harvey PD
    Int J Clin Pract; 2007 Jun; 61(6):896-902. PubMed ID: 17504351
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients.
    Ulrich S; Sandmann U; Genz A
    Pharmacopsychiatry; 2005 Jul; 38(4):171-7. PubMed ID: 16025420
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Depression as a risk factor in tardive dyskinesia.
    Rush M; Diamond F; Alpert M
    Biol Psychiatry; 1982 Mar; 17(3):387-92. PubMed ID: 6123350
    [No Abstract]   [Full Text] [Related]  

  • 57. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.
    Kane JM; Smith JM
    Arch Gen Psychiatry; 1982 Apr; 39(4):473-81. PubMed ID: 6121548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tardive dyskinesia in psychiatric outpatients: a study of prevalence and association with demographic, clinical, and drug history variables.
    Mukherjee S; Rosen AM; Cardenas C; Varia V; Olarte S
    Arch Gen Psychiatry; 1982 Apr; 39(4):466-9. PubMed ID: 6121547
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.
    Jeste DV; Caligiuri MP; Paulsen JS; Heaton RK; Lacro JP; Harris MJ; Bailey A; Fell RL; McAdams LA
    Arch Gen Psychiatry; 1995 Sep; 52(9):756-65. PubMed ID: 7654127
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The prevalence of tardive dyskinesia in fluphenazine-treated patients.
    Yassa R; Iskandar H; Ally J
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):17S-20S. PubMed ID: 3220966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.